Breakthrough Results with Tulisokibart in Ulcer...

By João L. Carapinha

June 23, 2026

Tulisokibart ulcerative colitis therapy has achieved a critical milestone, becoming the first anti-TL1A monoclonal antibody to demonstrate clinical remission at week 12 in a Phase 3 trial of patients with moderately to severely active disease. Dev...